ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MRK Merck and Co Inc

127.47
-0.79 (-0.62%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Merck and Co Inc NYSE:MRK NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.79 -0.62% 127.47 128.48 127.18 128.11 6,221,929 01:00:00

Merck President of Global Human Health to Step Down

10/12/2018 10:25pm

Dow Jones News


Merck (NYSE:MRK)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Merck Charts.

Merck & Co. Inc. (MRK) on Monday said Adam H. Schechter, president of Global Human Health, is stepping down from his current position as of Dec. 31, and will be shifting to an advisory capacity to the chief executive.

In addition, Merck said it "is taking the opportunity to reshape its commercial organization and is creating two new Executive Committee roles," promoting Frank Clyburn to chief commercial officer and Michael Nally to chief marketing officer.

Mr. Schechter, who joined the company in 1988, has been the president of Merck's human health business since 2010.

"Adam's leadership and unwavering dedication to finding new ways to bring Merck's medicines and vaccines to more patients around the world have been hallmarks of his time at Merck," Merck Chairman and Chief Executive Officer Kenneth C. Frazier said in a statement. "I have relied on his experience and expertise as we evolved a world-class commercial organization, spanning primary care, hospital and specialty, vaccines and oncology. Because of him we are better positioned to address future opportunities and challenges as a global biopharmaceutical company, and Frank and Mike have a great foundation upon which to build future success."

Mr. Clyburn and Mr. Nally will start their new roles on Jan. 1, 2019. Mr. Clyburn most recently has served as president of the Global Oncology business. Mr. Nally most recently led the company's Vaccines business.

 

Write to copydesk@dowjones.com

 

(END) Dow Jones Newswires

December 10, 2018 17:10 ET (22:10 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

1 Year Merck Chart

1 Year Merck Chart

1 Month Merck Chart

1 Month Merck Chart

Your Recent History

Delayed Upgrade Clock